Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Xentuzumab by Boehringer Ingelheim International for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Xentuzumab is under clinical development by Boehringer Ingelheim International and currently in Phase II for Human Epidermal Growth Factor Receptor...
Data Insights
Xentuzumab by Boehringer Ingelheim International for Non-Small Cell Lung Cancer: Likelihood of Approval
Xentuzumab is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer. According...